BioSpace News Archive

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that a poster describing translational data obtained in the DeCidE clinical study in patients with advanced, recurrent ovarian cancer will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 10-14, 2021 in Washington, DC.

Cerus Corporation Applauds FDA Requirements Effective Today to Safeguard the U.S. Platelet Supply

The SBIR/STTR Matching Fund Grant Will Advance the Company’s Innovation and Commercialization Efforts, and Job Creation

Citius Pharmaceuticals, Inc. announced that Citius Executive Chairman Leonard Mazur and his wife, Helena Mazur, were honored by Temple University, Philadelphia, PA, which renamed the main building housing the College of Liberal Arts to Leonard and Helena Mazur Hall in recognition of the Mazur’s longstanding commitment to Temple University’s students and alumni.

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that new data from two clinical studies and one research study will be presented during oral and poster sessions at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Washington, D.C.,

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced oral and poster presentations of clinical and non-clinical data for tumor infiltrating lymphocyte (TIL) cell therapies in multiple solid tumors will be presented at the 36thAnnual Meeting of the Society for Immunotherapy of Cancer (SITC).

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting,

T-knife Therapeutics, Inc. announced that three abstracts highlighting its lead product candidate TK-8001, a T cell receptor engineered T cell therapy being developed to treat MAGE-A1 positive solid tumors, will be presented at the upcoming Society for Immunotherapy of Cancer 36th Annual Meeting taking place November 10-14, 2021.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that multiple presentations of results from clinical and preclinical studies of seladelpar will be delivered during The Liver Meeting Digital Experience™ 2021 (TLMdX) of the American Association for the Study of Liver Diseases (AASLD).

Candel Therapeutics, Inc. (Nasdaq: CADL), today announced that its President and Chief Executive Officer, Paul Peter Tak, MD, PhD, FMedSci, and E. Antonio Chiocca, MD, PhD, FAANS, an investigator on Candel’s clinical trials in brain cancer, will present data and overviews pertaining to oncolytic viral immunotherapies for glioblastoma and other solid tumors at the following upcoming scientific conferences.